Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Salicyl-AMP ligase, also known as MbtA, is an enzyme that plays a critical role in the biosynthesis of mycobactin, a siderophore essential for iron acquisition in Mycobacterium tuberculosis. This enzyme catalyzes the first committed step in mycobactin biosynthesis, activating salicylic acid and transferring it to the aryl carrier protein MbtB. MbtA is considered an attractive target for novel antitubercular agents due to its essentiality in iron acquisition pathways unique to bacteria.
Inhibition of salicyl-AMP ligase disrupts mycobactin biosynthesis, leading to iron starvation and reduced bacterial growth and virulence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Salicyl-AMP ligase.